The cash flow of IMMUNITYBIO, INC. over the past 10 years
Chart IMMUNITYBIO, INC.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, IMMUNITYBIO, INC.'s operating cash flow was -$304.94M and its capital expenditures $4.25M, leaving free cash flow of -$309.19M. Free cash flow was below zero in all 10 years shown. It ranged from -$415.67M in fiscal 2022 to -$45.15M in fiscal 2016. Capital expenditures were highest in fiscal 2022, at $78.16M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$304.94M | $4.25M* | -$309.19M |
| 2024ended Dec 31, 2024 | -$391.24M | $6.89M | -$398.12M |
| 2023ended Dec 31, 2023 | -$366.76M | $30.58M | -$397.34M |
| 2022ended Dec 31, 2022 | -$337.51M | $78.16M | -$415.67M |
| 2021ended Dec 31, 2021 | -$274.42M | $33.56M | -$307.98M |
| 2020ended Dec 31, 2020 | -$171.72M | $1.67M | -$173.39M |
| 2019ended Dec 31, 2019 | -$152.11M | $4.29M | -$156.4M |
| 2018ended Dec 31, 2018 | -$63.38M | $13.1M | -$76.48M |
| 2017ended Dec 31, 2017 | -$48.78M | $34.81M | -$83.59M |
| 2016ended Dec 31, 2016 | -$38.59M | $6.56M | -$45.15M |
Fiscal years as IMMUNITYBIO, INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on IMMUNITYBIO, INC.
- The revenue of IMMUNITYBIO, INC.
- The profitability of IMMUNITYBIO, INC.
- The debt of IMMUNITYBIO, INC.
- All of IMMUNITYBIO, INC.'s financials, charted
Companies of a similar size
- BRXBrixmor Property Group Inc.
- TTMITTM TECHNOLOGIES, INC.
- REXRRexford Industrial Realty, Inc.
- DBXDropbox, Inc.
- ZETAZeta Global Holdings Corp.
Not investment advice. This page shows what IMMUNITYBIO, INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.